At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 09 Feb 2000 Discontinued-Preclinical for Benign prostatic hyperplasia in USA (Unknown route)
- 04 Feb 2000 No-Development-Reported for Benign prostatic hyperplasia in USA (Unknown route)
- 20 Feb 1997 New profile